First-in-human clinical trial confirmed novel HIV vaccine approach
On Feb. 3, 2021, IAVI and Scripps Research announced a phase 1 clinical trial testing a novel vaccine approach to prevent HIV that produced promising results.
The vaccine showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of participants who received the vaccine.
Tags:
Source: Scripps Research
Credit: Scanning electron micrograph of HIV-1 budding (in green) from cultured lymphocyte, courtesy: C. Goldsmith Content Providers: CDC/ C. Goldsmith, P. Feorino, E. L. Palmer, W. R. McManus, Centers for Disease Control and Prevention’s Public Health Image Library.
